IMPROVING TREATMENT DECISIONS FOR BREAST CANCER PATIENTS

That this House welcomes the National Institute for Health and Care Excellence's final guidance on the Oncotype DX breast cancer test; notes that this represents an important milestone in delivering personalised medicine to breast cancer patients in the NHS; recognises that this test will guide individual decisions about chemotherapy treatment; further notes that avoiding chemotherapy where it is unlikely to be beneficial could improve patient outcomes, reduce overtreatment and save the NHS between £7,500 to £10,000 per patient; and urges the Government to encourage swift uptake of the Oncotype DX across the NHS and to ensure patients have fair and equitable access by developing a national commissioning policy for the test as soon as possible.